気になる企業 – AMGEN – オリジナルのmAb/BiTE antibody – Biosimilarも手がけるBiologicsの雄 – ID18102 [2020/06/24]

AMGEN

独自技術

• BiTE (Bispecific T cell Engager) antibody

売上規模

2019年の売り上げ。

• 2019年売り上げ 約2.3兆円
• BEVENITY (romosozumab-aqqg)の売り上げは、約189億円
• AMGEVITA (adalimumab)の売り上げは、約215億円
• KANJINTI (trastuzumab-anns)の売り上げは、226億円

AMGEN Press Release
Amgen Reports Fourth Quarter And Full Year 2019 Financial Results, AMGEN – サイトより

http://investors.amgen.com/news-releases/news-release-details/amgen-reports-fourth-quarter-and-full-year-2019-financial/

Product Pipeline

• AIMOVIG (erenumab-aooe)
  • Therapeutic Area : Neuroscience
  • Modality : mAb
  • Target : CGRP-R (calcitonin gene-related peptide receptor)
  • Initial U.S. Approval: 2018
  • 70mg/month
• PROLIA (denosumab)
  • Therapeutic Area : Bone
  • Modality : mAb
  • Initial U.S. Approval : 2010
• REPATHA (evolocumab)
  • Therapeutic Area : Cardiovascular
  • Modality : mAb
  • Initial U.S. Approval : 2015
• TEZEPELUMAB
  • Therapeutic Area : Inflammation
  • Modality : mAb
• ABP 798 (biosimilar rituximab)
  • Therapeutic Area : Hematology / Oncology
  • Moality : mAb
• ABP 959 (Biosimilar eculizumab)
  • Therapeutic Area : Hematology / Oncology
  • Modality : mAb
• BLINCYTO (blinatumomab)
  • Therapeutic Area : Hematology / Oncology
  • Modality : BiTE Ab
  • Target : CD-19 x CD3 BiTE
  • Initial U.S. Approval: 2014
  • 20mg/maximum
• その他 BiTE Antibody : 11 products
• EVENITY (romosazumab-aqqg)
  • Therapeutic Area : Bone
  • Modality : mAb
  • Target : sclerostin
  • Initial U.S. Approval : 2019
  • 210mg/month
• AMG 714/PrV-015
  • Therapeutic Area : Inflammation
  • Modality : mAb
• AMG 404
  • Therapeutic Area : Hematology / Oncology
  • Modality : mAb
• AMG 430
  • Therapeutic Area : Infalmmation
  • Modality : mAb
• IMLYGIC (talimogene Laherparepvec)
  • Therapeutic Area : Hematology / Oncology
  • Modality : Oncolytic Immunotherapy
  • Target : HSV-1 vector with KEYTRUDA (Anti PD-1, Merck & Company)
  • Initial U.S. Approval : 2015
  • 1e6 PFU/mL x 4mL, subsequent: 1e8 PFU/mL x 4mL
• CAR T
  • AMG 119
    • Therapeutic Area : Hematology / Oncology
    • Modality : CAR T
• Small Molecule
  • KYPROLIS
  • OMECAMTIV MECARBIL
  • OTEZLA
  • AMG 510
  • AMG 199
  • AMG 397
  • AMG 594
• Peptibody
  • NPLATE (romiplostim)
  • PARSABIV (etelcalcetide)
• Bispecific Antibody
  • ROZIBAFUSP ALFA
• Fusion Protein
  • AMG 171
• XmAb Antiboldy
  • AMG 424
• DARPin protein
  • AMG 506
• siRNA
  • AMG 890
    • Therapeutic Area : Cardiovascular
    • Modality : mAb

AMGEN

PIPELINE 2020/06

https://www.amgenpipeline.com

編集履歴
2020/06/19 はりきり(MR)
2020/06/24 追加(RocheのBiosimilar戦略, 2015版)

Biosimilar

PfizerのBiosimilarの売り上げは、約319億円(2016)から約1,000億円(2020)に伸長し、その後、2027には、6,000億円を見込む^Forbes。

• AMJEVITA (adalimumab-atto), injection (40mg/0.8mL, 20mg/0.4mL)
  • Initial U.S. Approval: 2016
• AVSOLA (infliximab-axxq), injection (100mg/vial)
  • Initial U.S. Approval: 2019
• KANJINTI (trastumumab-anns), injection (420mg/vial)
  • Initial U.S. Approval: 2019
• MVASI (bevacizumab-awwb), injection (100mg/vial, 400mg/vial)
  • Initial U.S. Approval: 2017)

FDA-Approved Biosimilar Products

AMGEN サイト – より

https://www.amgenbiosimilars.com/products/approved-products/